Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock, $0.001 par value per share · CUSIP: 05338F306

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 1,286,909.00 · Class: 6.8%

  • BVF I GP LLC

    Shares: 1,286,909.00 · Class: 6.8%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 500,507.00 · Class: 2.7%

  • BVF II GP LLC

    Shares: 500,507.00 · Class: 2.7%

  • Biotechnology Value Trading Fund OS LP

    Shares: 97,524.00 · Class: 0.5%

  • BVF Partners OS Ltd.

    Shares: 97,524.00 · Class: 0.5%

  • BVF GP HOLDINGS LLC

    Shares: 1,787,416.00 · Class: 9.4%

  • BVF PARTNERS L P/IL

    Shares: 1,904,257.00 · Class: 9.99%

  • BVF INC/IL

    Shares: 1,904,257.00 · Class: 9.99%

  • LAMPERT MARK N

    Shares: 1,904,257.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-26-000454
Form type
SCHEDULE 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub